LOX and neoplasm: Inhibitors of LOX enzymatic activity such as beta-aminopropionitrile (BAPN) were tested in combination with PD-1 treatment in mouse models leading to tumor reduction and increased T-cell infiltration [138], however the clinical use of BAPN is impeded by concerns regarding toxicities [139].